ニュース

OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.

The average brokerage recommendation (ABR) for Veeva (VEEV) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Veeva Systems Inc. (NYSE:VEEV) is among the 10 Stocks That Will Make You Rich Over the Next Decade. It is considered a high-quality, long-term growth stock given its robust return on capital, free cash flow margin, and 5-year revenue growth estimates. This is helping drive strong institutional interest in the company. According to Insider Monkey’s database […]

Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead

In early May 2026, Smith+Nephew announced it is unifying its quality management on Veeva Quality Cloud, adopting Veeva QualityDocs, QMS, and Training to manage controlled content, global processes, and more than 500,000 annual trainings. This expands Veeva’s footprint in medtech and highlights how deeply its cloud platform can become embedded in mission-critical, compliance-heavy workflows. We’ll now examine how Smith+Nephew’s move to Veeva Quality Cloud may reinforce Veeva’s AI-led CRM and...

A number of stocks fell in the morning session after the April PPI report sent Treasury yields to 10-month highs, with the 10-year yield rising to 4.49%.

This technology firm delivers SaaS and AI-driven workflow solutions for leading players in the property and casualty insurance sector.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

VEEV expands Vault CRM adoption and AI capabilities with Roche and BioMarin partnerships as life sciences firms modernize workflows.

Veeva Systems (VEEV) closed the most recent trading day at $156.33, moving 1.94% from the previous trading session.

Doximity (DOCS) delivered earnings and revenue surprises of -7.14% and +1.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Veeva Systems expands its medtech reach as Smith+Nephew adopts Veeva Quality Cloud to modernize global quality operations and training.

VEEV is expanding partnerships, growing Vault CRM adoption and boosting AI capabilities with its Ostro acquisition.

The fair value estimate for Veeva Systems sits at US$264.46, holding steady even as the broader software sector sees shifting valuations. Analysts link this unchanged target to a mix of confidence in Veeva's recent Q4 execution and caution around longer term questions on AI, R&D growth, and CRM commitments. As you read on, you will see how these competing views are shaping the evolving story around the stock and what signals to watch next. Stay updated as the Fair Value for Veeva Systems...

Client wins and data partnerships put Veeva’s workflow role in focus Veeva Systems (VEEV) just secured Smith+Nephew’s global quality management rollout on Veeva Quality Cloud, alongside a new Snowflake data partnership, putting fresh attention on how deeply its software sits in life sciences workflows. Smith+Nephew plans to use Veeva QualityDocs as a single source for quality controlled content, Veeva QMS to align processes globally, and Veeva Training to manage more than 500,000 annual...

OPRX launched a programmatic EHR ad connection for DSPs, expanding point-of-care targeting and access to authenticated inventory.

Veeva Systems (NYSE:VEEV) recently announced a new collaboration with Smith+Nephew to centralize global quality management on Veeva Quality Cloud. The company also entered a partnership with Snowflake to connect the Veeva Vault Platform with Snowflake’s AI Data Cloud for life sciences data and analytics. These agreements position Veeva’s platforms more deeply within regulated, data intensive pharma and medtech workflows. Veeva Systems, trading at around $159.33, operates at the intersection...

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -519.58% and -1.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Veeva Systems Inc. (NYSE:VEEV) is one of the best stocks to buy with wide moats. The latest moat-relevant update came on May 6, 2026, when Snowflake said it was collaborating with Veeva Systems Inc. (NYSE:VEEV) to connect the Snowflake AI Data Cloud for Healthcare & Life Sciences with the Veeva Vault Platform. The new Snowflake […]

HIMS first-quarter 2026 results are likely to benefit from Labs and branded weight loss medications even as higher costs and GLP-1 scrutiny linger.

Investors may be wondering whether Veeva Systems at about US$168.25 is starting to look interesting, or if the stock still carries too much optimism in its price. Over the last week the share price has moved by 7.9%, compared with a 2.5% decline over 30 days and deeper returns of 23.3% year to date and 29.8% over the past year. Recent coverage has focused on Veeva Systems as a key healthcare software provider, with attention on how its role in life sciences workflows might affect sentiment...

Zacks.com users have recently been watching Veeva (VEEV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Enovis (ENOV) delivered earnings and revenue surprises of +8.54% and +3.68%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

In the closing of the recent trading day, Veeva Systems (VEEV) stood at $167.29, denoting a -2.28% move from the preceding trading day.

Veeva’s upcoming S&P 500 inclusion could bring fresh index-driven demand to a high-margin software stock still trading far below its 52-week high.